<\/p>\n
Temotero<\/strong> is an oral capsule from Glenmark containing temozolomide<\/strong> p\u00e5 20 mg and 100 mg<\/strong> — an oral alkylating cytotoxic agent and the standard chemotherapy for glioblastoma multiforme (GBM)<\/strong> og anaplastic astrocytoma<\/strong>. Standard regimen: concurrent<\/strong> with radiotherapy (75 mg\/m² daily for 6 weeks), then maintenance<\/strong> 150–200 mg\/m² daily for days 1–5 of each 28-day cycle for 6 cycles (Stupp protocol). Ta p\u00e5 tom mage<\/strong> at the same time each day, with antiemetic (ondansetron) 1 hour before. Mandatory: PCP-profilakse<\/strong> with co-trimoxazole during radiotherapy phase. FBC weekly during concurrent phase, then before each maintenance cycle.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n Temotero is an oral capsule from Glenmark containing temozolomide<\/strong> (20 mg and 100 mg). Temozolomide is an oral alkylating cytotoxic agent of the imidazotetrazine class. It crosses the blood-brain barrier (CSF concentration ~30% of plasma) and is the only oral cytotoxic with proven survival benefit in glioblastoma multiforme. Standard combination with radiotherapy (the “Stupp protocol”, 2005) extended median GBM survival from 12 months to 15 months and 2-year survival from 11% to 27%.<\/p>\n Vanlig:<\/strong> nausea, vomiting (mostly preventable with ondansetron), fatigue, anorexia, constipation, headache, alopecia.<\/p>\n Viktig:<\/strong><\/p>\nWhat Is Temotero?<\/h2>\n
Bruk og indikasjoner<\/h2>\n
\n
Dosage (Stupp protocol)<\/h2>\n
\n
\n
Bivirkninger<\/h2>\n
\n
Advarsler<\/h2>\n
\n
Legemiddelinteraksjoner<\/h2>\n